Does remdesivir have any neuropsychiatric adverse effects? by Gulati, Gautam & Kelly, B.D.
Correspondence
Irish Journal of Psychological Medicine, 00 (2020).
doi:10.1017/ipm.2020.67
Does remdesivir have any neuropsychiatric adverse effects?
On 1 May 2020, the US Food and Drug Administration
issued an emergency use authorisation for remdesivir
in the treatment of hospitalised COVID-19 patients
(Food and Drug Administration, 2020). Remdesivir is
a nucleotide analogue antiviral drug. It is an investiga-
tional drug against COVID-19 and to date there is
relatively little known about remdesivir from human
trials.
Experience from previous viral pandemics suggests
that the immunological response to viruses themselves
has the potential to cause neuropsychiatric manifesta-
tions including encephalopathies and psychosis
(Troyer et al. 2020). It is too early in the course of the
current COVID-19 pandemic to evaluate such associa-
tions for COVID-19 (Bilbul et al. 2020). Antiviral
drugs, such as those used in the treatment of human
immunodeficiency viruses, have been associated with
effects on the central nervous system; neuropsychiatric
manifestations include mania and psychoses (Abers
et al.2014). Little is known, however, about the potential
neuropsychiatric adverse effects of remdesivir.We con-
ducted a PubMed search to elicit any early reports of
such effects.
Evidence from Ebola virus disease
In a case report of remdesivir therapy for Ebola menin-
goencephalitis treated with high-dose corticosteroids
and intravenous remdesivir therapy, no serious clinical
or biochemical events were reported apart from a
transient rise in serum amylase level (Jacobs et al. 2016).
One patient experienced neurological complications
after receiving remdesivir for Ebola treatment in a
phase 1 study; however, it was not clear if this was
due exclusively to having received remdesivir
(EuropeanMedicines Agency Committee for Medicinal
Products for Human Use, 2016; Barlow et al. 2020).
No adverse effectswere recorded in a neonate treated
with remdesivir for Ebola in Guinea (Dörnemann
et al. 2017).
A randomised controlled trial (RCT) with remdesi-
vir as one of four agents for Ebola virus in 175 patients
in the Democratic Republic of Congo limited enrolment
during the trial to two non-remdesivir agents once two
of the other trial agents had shown superiority over
remdesivir in respect ofmortality outcomes. Therewere
no significant clinical or biochemical side effects related
to remdesivir apart from one report of hypotension
and death possibly related to the drug (Mulangu
et al. 2019).
Evidence from COVID-19 disease
An RCT of intravenous remdesivir in Hubei, China in
COVID-19 patients found no aggravation of depression
or schizophrenia leading to treatment discontinuation
in the treatment group of 158 patients (Wang et al. 2020).
A case report of a COVID-19 patient from
Washington, USA treated with remdesivir reported
no significant adverse effects (Holshue et al. 2020).
Of the first 12US patientswith COVID-19 confirmed
by the Centre for Disease Control, 3 patients received
remdesivir. After starting remdesivir, all patients
had transient gastrointestinal symptoms. No other
post-remdesivir symptoms were observed (Kukawski
et al. 2020).
In an open-label cohort of 61 COVID-19 patients
from the USA, Canada, Europe and Japan, 60%
reported adverse events. The most common adverse
events were increased hepatic enzymes, diarrhoea,
rash, renal impairment and hypotension. Delirium
was reported in two patients (Grein et al. 2020).
The Adaptive COVID-19 Treatment Trial recruited
patients from 68 sites worldwide. Data on adverse
effects are yet to be published (National Institute of
Allergy and Infectious Diseases, 2020).
A study of remdesivir use in four COVID-19
patients in Naples, Italy (Durante-Mangoni et al.,
2020) highlighted a predominantly cardiac and hepatic
adverse effect profile.
A prospective, open-label study of remdesivir,
conducted in Milan, Italy, with 35 COVID-19 patients
found that the adverse effect profile included increased
liver enzymes, acute renal injury and in one case a
serious maculo-papular rash (Antinori et al. 2020).
Summary
The limited data available do not seem to highlight any
specific neuropsychiatric adverse effects associated
with remdesivir, save for the occurrence of delirium
in two patients in one open-label study in COVID-19
disease (Grein et al. 2020) and a possible report of
neurological complications in a phase 1 trial in Ebola
virus disease (Barlow et al. 2016). This position cannot,
however, be taken as definitive because it is not known
whether trial protocols specifically evaluated for such
effects, apart from the RCT in Hubei in which placebo
(but not remdesivir) was associated with exacerbation
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of depression and schizophrenia (Wang et al. 2020).
Further, this preliminary review did not use a system-
atic review methodology. Remdesivir is a drug that is
investigational and trial data are limited. The neuropsy-
chiatric adverse effect profile, if any, will only become
apparent following controlled trials with large
sample sizes.
Conflicts of interest
GG and BDK have no conflicts of interest to declare.
References
Abers MS, Shandera WX, Kass JS (2014). Neurological
and psychiatric adverse effects of antiretroviral drugs.
CNS Drugs 28, 131–145.
Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C,
Pagani G, Gubertini G, Coen M, Magni C, Castelli A,
Borghi B, Colombo R, Giorgi R, Angeli E, Mileto D,
Milazzo L, Vimercati S, Pellicciotta M, Corbellino M,
Torre A, Rusconi S, Oreni L, Gismondo MR,
Giacomelli A, Meroni L, Rizzardini G, Galli M (2020).
Compassionate remdesivir treatment of severe Covid-19
pneumonia in intensive care unit (ICU) and Non-ICU
patients: Clinical outcome and differences in
post_treatment hospitalisation status. Pharmacol Res
104899. doi: 10.1016/j.phrs.2020.104899. [Epub ahead of
print]
Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ,
Claassen CW, Heavner MS (2020). Review of emerging
pharmacotherapy for the treatment of Coronavirus
Disease 2019. Pharmacotherapy 40, 416–437. doi: 10.1002/
phar.2398
Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL
(2020). Psychopharmacology of COVID-19. Psychosomatics.
doi: 10.1016/j.psym.2020.05.006. [Epub ahead of print]
Dörnemann J, Burzio C, Ronsse A, Sprecher A, De Clerck
H, Van Herp M, Kolié MC, Yosifiva V, Caluwaerts S,
McElroy AK, Antierens A (2017). First newborn baby to
receive experimental therapies survives Ebola Virus
Disease. The Journal of Infectious Diseases 215, 171–174. doi:
10.1093/infdis/jiw493.
Durante-Mangoni E, Andini R, Bertolino L, Mele F, Florio
LL, Murino P, Corcione A, Zampino R (2020). Early
experience with remdesivir in SARS-CoV-2 pneumonia.
Infection 2020 May 16, 1–4. doi: 10.1007/s15010-020-01448-
x. [Epub ahead of print].
European Medicines Agency Committee for Medicinal




ebola_en.pdf). Accessed 22nd May, 2020.
Food and Drug Administration (2020). Emergency
use authorisation for remdesivir. (https://www.fda.
gov/media/137564/download). Accessed 2nd May
2020.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E,
Castagna A, et al. (2020). Compassionate use of
remdesivir for patients with severe Covid-19. New
England Journal of Medicine 2020. doi: 10.1056/
NEJMoa2007016. [Epub ahead of print]
Holshue ML, DeBolt C, Lindquist S, Lindquist S,
Lofy KH, Wiesman J, et al. (2020). First case of
2019 novel coronavirus in the United States. New England
Journal of Medicine 382, 929–936. doi: 10.1056/
NEJMoa2001191.
Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I,
Filipe A (2016). Late Ebola virus relapse causing
meningoencephalitis: a case report. Lancet 338, 498–503.
Kukawski SA, Wong KK, Collins JP, Epstein L, Killerby
ME, Midgley CM, et al. (2020). First 12 patients with
coronavirus disease 2019 (COVID-19) in the United States.
medRxiv. Pre-print. (https://europepmc.org/article/ppr/
ppr117009#impact). Accessed 2nd May 2020. doi: 10.
1101/2020.03.09.20032896
Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O,
Proschan M, Mukadi D (2019). A randomized, controlled
trial of Ebola virus disease therapeutics. New England
Journal of Medicine 381, 2293–2303.
National Institute of Allergy and Infectious Diseases
(2020). NIH Clinical Trial Shows Remdesivir Accelerates
Recovery from Advanced COVID-19. 2020. Online
publication: (https://www.niaid.nih.gov/news-events/
nih-clinical-trial-shows-remdesivir-accelerates-recovery-
advanced-covid-19). Accessed 2nd May 2020.
Troyer EA, Kohn JN, Hong S (2020). Are we facing a
crashing wave of neuropsychiatric sequelae of COVID-19?
Neuropsychiatric symptoms and potential immunologic
mechanisms. Brain, Behavior, and Immunity S0889-1591(20)
30489-X. https://doi.org/10.1016/j.bbi.2020.04.027 [Epub
ahead of print]
Wang Y, Zhang D, Du G, Du PR, Zhao PJ, Jin PY, et al.
(2020). Remdesivir in adults with severe COVID-19:
a randomised, double-blind, placebo-controlled, multi-
centre trial. Lancet 2020. doi: https://doi.org/10.1016/
S0140-6736(20)31022-9 [Epub ahead of print].
G. GULATI




Department of Psychiatry, Trinity College Dublin, Dublin, Ireland
2 G. Gulati and B. D. Kelly
